Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.41 |
| ▸ | SCD | O00767 | 3/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448886 | 0.91 | KIT (0.43) | EGFRSLC9A1CSNK2A1MALT1ABL1 | |
| SCHEMBL3449527 | 0.91 | CSNK2A1 (0.43) | EGFRSLC9A1CSNK2A1SCDMALT1 | |
| SCHEMBL3458418 | 0.90 | P2RY12 (0.45) | F11KLKB1EGFRSLC9A1PAK1 | |
| SCHEMBL3447674 | 0.88 | JAK3 (0.43) | EGFRPAK1CSNK2A1ABL1BCR | |
| SCHEMBL3449234 | 0.88 | XDH (0.43) | EGFRPAK1CSNK2A1ABL1BCR | |
| SCHEMBL3450271 | 0.88 | CSNK2A1 (0.42) | EGFRSLC9A1CSNK2A1MALT1XDH | |
| SCHEMBL3455060 | 0.88 | MALT1 (0.47) | EGFRSLC9A1CSNK2A1MALT1 | |
| SCHEMBL3449427 | 0.88 | AXL (0.50) | EGFRPAK1CSNK2A1XDHSLC22A12 | |
| SCHEMBL3449464 | 0.88 | SLC9A1 (0.44) | EGFRSLC9A1 | |
| SCHEMBL3447741 | 0.88 | JAK3 (0.44) | EGFRPAK1CSNK2A1ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | F11 1988/4885KLKB1 3726/4885EGFR 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.